These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 11880946)

  • 1. [Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients].
    Briken P; Nika E; Krausz M; Naber D
    Fortschr Neurol Psychiatr; 2002 Mar; 70(3):139-44. PubMed ID: 11880946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
    Keck PE; Strakowski SM; McElroy SL
    J Clin Psychiatry; 2000; 61 Suppl 3():4-9. PubMed ID: 10724127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
    Buckley PF
    J Clin Psychiatry; 1999; 60 Suppl 10():52-60. PubMed ID: 10340688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
    Citrome L; Volavka J; Czobor P; Sheitman B; Lindenmayer JP; McEvoy J; Cooper TB; Chakos M; Lieberman JA
    Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
    Bitter I; Czobor P; Dossenbach M; Volavka J
    Eur Psychiatry; 2005 Aug; 20(5-6):403-8. PubMed ID: 16084068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].
    Möller HJ
    Nervenarzt; 2000 May; 71(5):345-53. PubMed ID: 10846709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Viewpoint of schizophrenic patients: a European survey].
    Courtet P
    Encephale; 2001; 27(1):28-38. PubMed ID: 11294036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical neuroleptics in child and adolescent psychiatry.
    Remschmidt H; Hennighausen K; Clement HW; Heiser P; Schulz E
    Eur Child Adolesc Psychiatry; 2000; 9 Suppl 1():I9-19. PubMed ID: 11140784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
    Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
    Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
    Volavka J; Czobor P; Nolan K; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Lieberman JA
    J Clin Psychopharmacol; 2004 Apr; 24(2):225-8. PubMed ID: 15206671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia.
    Bilici M; Cakirbay H; Guler M; Tosun M; Ulgen M; Tan U
    Int J Neurosci; 2002 Jul; 112(7):817-28. PubMed ID: 12424822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials.
    Aleman A; Kahn RS
    Eur Neuropsychopharmacol; 2001 Aug; 11(4):289-93. PubMed ID: 11532383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neuroleptics and cognition].
    Brunnauer A; Geiger E; Laux G
    Psychiatr Prax; 2003 May; 30 Suppl 2():S106-9. PubMed ID: 14509053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of risperidone and olanzapine on the indications for clozapine.
    Ganguli R; Brar JS
    Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
    Heresco-Levy U; Ermilov M; Shimoni J; Shapira B; Silipo G; Javitt DC
    Am J Psychiatry; 2002 Mar; 159(3):480-2. PubMed ID: 11870017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia treatment: the use of atypical drugs--risperdal, zyperexa, and clozaril.
    Kalinyak CM
    Int J Psychiatr Nurs Res; 1998 Sep; 4(2):445-51. PubMed ID: 10451301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The promise of new drugs for schizophrenia treatment.
    Tamminga CA
    Can J Psychiatry; 1997 Apr; 42(3):265-73. PubMed ID: 9114942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agranulocytosis and neutropenia with typical and atypical neuroleptics.
    Hong X; Wang X
    Am J Psychiatry; 2001 Oct; 158(10):1736-7. PubMed ID: 11579015
    [No Abstract]   [Full Text] [Related]  

  • 20. Cognitive deficit in schizophrenia and its neurochemical basis.
    Breier A
    Br J Psychiatry Suppl; 1999; (37):16-8. PubMed ID: 10211135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.